Business Context and Reporting Period
This Form 8-K Current Report was filed by Henry Schein, Inc. on April 23, 2018. The filing reports a significant executive departure and the associated compensatory arrangements effective as of the filing date.
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial data provided relates to the specific severance package for the departing executive:
- Severance Duration: 18 months of continued base salary.
- Health Benefits: Continued coverage with waived COBRA premiums for the 18-month period.
- Bonus Compensation: Full 2018 target bonus plus a pro-rated portion of the 2019 target bonus through October 23, 2019.
- Equity: Full vesting of sign-on restricted stock and a cash payment equivalent to the 2017 LTIP grant vesting through the end of the severance period.
- Transition Costs: $85,000 for life/disability policy conversions and miscellaneous items.
Material Changes
The primary material change reported is the departure of Karen Prange, who served as Executive Vice President of the Company and Chief Executive Officer of the Global Animal Health, Medical, and Dental Surgical Group. She resigned effective April 23, 2018.
Outlook, Risks, and Unusual Items
Management Commentary and Arrangements:
- Ms. Prange executed a Release in favor of the Company in exchange for the severance benefits.
- The Release subjects Ms. Prange to restrictive covenants for a period between 18 and 36 months following her resignation.
- The full text of the Release is attached as Exhibit 10.1.
Risks and Contingencies:
- The filing notes that the description of the Release is not complete and is qualified by the full document.
- There is no explicit discussion of operational risks or future guidance in this specific filing.
Investor Verification Checklist
- Verify the impact of Ms. Prange's departure on the Global Animal Health, Medical, and Dental Surgical Group operations.
- Review the full text of the Release agreement (Exhibit 10.1) for specific restrictive covenant details.
- Confirm the appointment of a successor for the CEO role of the Global Animal Health, Medical, and Dental Surgical Group.
- Assess the total cost of the severance package relative to the company's annual compensation expenses.